| 1 |
30910587 | Epigenetic regulation of UDP-Glucuronosyltransferase by microRNA-200a/-183: implications for responses to sorafenib treatment in patients with hepatocellular carcinoma. | 2019 Jul 10 |
2 |
| 2 |
22736425 | Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma. | 2013 Jan 1 |
1 |
| 3 |
23673446 | Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma. | 2013 Jul |
1 |
| 4 |
22307138 | Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. | 2012 Apr 1 |
5 |
| 5 |
22912756 | Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study. | 2012 |
3 |
| 6 |
20706860 | Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. | 2011 Dec |
1 |
| 7 |
21235620 | Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors. | 2011 Jun |
1 |
| 8 |
21911167 | Using sorafenib for recurrent hepatocellular carcinoma after liver transplantation--interactions between calcineurin inhibitor: two case reports. | 2011 Sep |
1 |
| 9 |
16133532 | Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. | 2006 May |
1 |